Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by inthnoon Nov 08, 2022 5:34pm
188 Views
Post# 35083612

RE:Single Licensing Deal ?

RE:Single Licensing Deal ?
This is a tough one for sure and am guessing it is a strategy which onc has set out with the help of the 2 new board members to help put the most pressure on Roche and Pfizer. IMO only this statement now sets the stage for a buyout rather than a partnership but either would be good and a partnership could still be beneficial to both and the other idication could then be farmed out to the other BP. Both indications are huge and are needed in the world today so there is no way that if there is one licensing deal that they would only advance the one trial.
Everyone would need to work together to expeditiously advance these trials. All for Panc will be known in less than a week and my guess is that pfizer is getting as much up to date with Bracelet as possible to help in making a qualified decision. My guess is that we will either have a partneship deal or buyout before the Bracelet results are released.
<< Previous
Bullboard Posts
Next >>